Regeneron’s rare disease drug succeeds in Phase 3 studynews2025-08-26T15:52:53+00:00August 26th, 2025|Endpoints News|
Novartis pays $30M to Leqembi creator for access to blood-brain barrier technews2025-08-26T15:05:22+00:00August 26th, 2025|Endpoints News|
BeOne to get $885M upfront in royalty deal over Amgen’s Imdelltranews2025-08-25T16:02:36+00:00August 25th, 2025|Endpoints News|
AbbVie to buy psychedelic drug from partner Gilgameshnews2025-08-25T14:56:10+00:00August 25th, 2025|Endpoints News|
Gilead joins the in vivo cell therapy race with $350M buyout of Interiusnews2025-08-21T15:31:42+00:00August 21st, 2025|Endpoints News|
XOMA buys third biotech this month, as it swoops up Mural Oncologynews2025-08-20T14:51:31+00:00August 20th, 2025|Endpoints News|
With $42M, Jazz turns to Copenhagen biotech to build out epilepsy pipelinenews2025-08-20T14:37:19+00:00August 20th, 2025|Endpoints News|
Roivant-backed VantAI and Halda line up $1B RIPTAC pactnews2025-08-19T12:00:33+00:00August 19th, 2025|Endpoints News|
Genentech ends up to $2B cell therapy collab with Adaptivenews2025-08-18T15:33:05+00:00August 18th, 2025|Endpoints News|
Skyhawk’s RNA mission gets another $2B lift via Merck KGaAnews2025-08-18T12:00:55+00:00August 18th, 2025|Endpoints News|
